Kuwa Free! - Live Free!

NCT ID: NCT05044962

Last Updated: 2025-04-10

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 700 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-11-26
• Study Completion Date: 2026-03-31

Brief Summary

The study investigators are conducting foundational pharmacokinetic (PK) and qualitative studies, among 15-24 years old (inclusive) adolescent girls and young women living with HIV (AGYWLHIV) already on oral antiretroviral therapy (ART) and virally suppressed, leading up to a hybrid type I effectiveness-implementation trial randomizing individual AGYWLHIV to receive long-acting (LA) injectable cabotegravir/rilpivirine vs. standard of care within one of Kenya's largest HIV treatment programs. The PK and qualitative studies will investigate potential issues arising from co-delivery and guide delivery of the effectiveness-implementation trial. The PK and qualitative studies will largely be conducted with a sentinel cohort of AGYWLHIV. Learning from this early LA ART use, the investigators will refine the procedures in the LA ART hybrid trial.

Detailed Description

Long-acting (LA) antiretroviral therapy (ART), such as injectable cabotegravir and rilpivirine, has been receiving global clinical approvals and has the potential to address barriers to ART and improve patient adherence and persistence to treatment. LA ART regimens can potentially also increase options for patients and providers to individualize treatment plans, provide a powerful treatment option for those experiencing adherence issues related oral treatment options, and may ease the burden of health systems in RLS. Another major threat to AGYW's health is unintended pregnancies and AGYWLHIV also face unique challenges in uptake and continuation of LA contraceptives. Use of LA ART may foster synergy in usage of LA contraceptives among AGYWLHIV.

This proposed research study has three main components: 1) a prospective, non-randomized, parallel-group pharmacokinetic (PK) study among a sentinel cohort of five distinct groups of AGYW, and will leverage existing control groups (Aim 1a); 2) a qualitative study that will conduct individual interviews with four different subgroups of AGYWLHIV from the sentinel cohort from the PK study, as well as focus group discussions with providers, policy makers, and other stakeholders for health systems readiness for wider scale-up (Aim 1b); and 3) an open-label, mixed methods, 48-week type I hybrid trial randomizing AGYW with viral suppression on their current ART regimen to switch to 1:1 cabotegravir/ rilpivirine (intervention arm) vs. continue their oral ART regimen (Aim 2a), with a component also evaluating implementation outcomes of acceptability, feasibility, and fidelity (Aim 2b). The proposed study will be conducted in HIV treatment facilities in western Kenya within the regional Moi Teaching and Referral Hospital (MTRH).

This study will provide foundational data for future studies and implementation plans related to addressing barriers and will critically inform follow-up studies of LA ART in other priority subpopulations. Providing an array of method options for both HIV treatment and pregnancy prevention has the potential to revolutionize personal decision-making and improve long-term outcomes for AGYWLHIV. Our real-world experiences of co-delivery will also inform future considerations for co-formulations of antiretrovirals and contraceptives for both HIV treatment and prevention.

Our central hypothesis is the following: 1) at the client level, the use of LA ART or contraceptives will foster long-term thinking for health, forging a convergence of the use of the two when applicable; and 2) at the program/provider level, leveraging existing LA contraceptive delivery platform will make LA ART highly acceptable, feasible, and deliverable with high fidelity.

Our overall objective in this study is to conduct the foundational PK and qualitative studies first as a lead in to the hybrid trial. Guided by Proctor et al.'s implementation outcomes framework, the hybrid trial will also focus on acceptability, feasibility, and fidelity. These implementation outcomes are proximal indicators of implementation processes and intermediate outcomes, which ultimately predict implementation success. Demonstrating successful implementation outcomes will then inform wider-scale implementation of LA ART, when service and client outcomes can be fully realized.

The PK and qualitative studies will investigate potential issues arising from co-delivery and guide delivery of the effectiveness-implementation trial. The PK (Aim 1a) and qualitative (Aim 1b) studies will largely be conducted with a sentinel cohort of AGYWLHIV in parallel to each other. Learning from this early LA ART use, the investigators will refine our procedures in the LA ART hybrid trial (Aim 2). For all possible outcomes/scenarios of Aim 1, the investigators still anticipate conducting a robust trial in Aim 2.

Thus, our specific aims are:

Aim 1: To collect foundational data to better inform design of an effectiveness-implementation trial.

Aim 1a: To determine if combined cabotegravir/rilpivirine injectable use has bidirectional drug-drug interactions with injectable (depot medroxyprogesterone acetate [DMPA]) or implantable (etonogestrel or levonorgestrel) contraceptives.

Aim 1b: To qualitatively explore points of convergence and divergence, preferences and values, and health systems readiness around wider-scale co-delivery of LA ART and contraceptives.

Aim 2: To evaluate the impact of clinic-provided, co-delivery of LA ART and contraceptives among AGYWLHIV.

Aim 2a: To evaluate the impact on effectiveness outcomes of HIV treatment (viral suppression and adherence/persistence) and contraception (uptake and continuation rates).

Aim 2b: To evaluate the impact on implementation outcomes of acceptability, feasibility, and fidelity.

Conditions

HIV Infections; Contraception; Drug-drug Interaction

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Aim 1a (PK study group 1)

Initiating injectable cabotegravir/rilpivirine (LA ART) and DMPA

Group Type: EXPERIMENTAL

Cabotegravir/ Rilpivirine

Intervention Type: DRUG

For initial injection participants will be given CABENUVA 600-mg/900-mg Kit: (single-dose vial of 600 mg/3 mL (200 mg/mL) cabotegravir , single-dose vial of 900 mg/3 mL (300 mg/mL) rilpivirin).

For subsequent injections participants will be given CABENUVA 400-mg/600-mg Kit: (single-dose vial of 400 mg/2 mL (200 mg/mL) cabotegravir, single-dose vial of 600 mg/2 mL (300 mg/mL) rilpivirine)

CABENUVA® is owned by or licensed to the ViiV Healthcare group of companies, GlaxoSmithKline Research Triangle Park, NC 27709

Intramuscular depo-medroxyprogesterone acetate (IM DMPA)

Intervention Type: DRUG

DMPA (150 mg of depo-medroxyprogesterone acetate (MPA)/ml IMI) is the most commonly used injectable contraceptive worldwide

Aim 1a (PK study group 2)

Initiating injectable cabotegravir/rilpivirine (LA ART) and and etonogestrel implant

Group Type: EXPERIMENTAL

Cabotegravir/ Rilpivirine

Intervention Type: DRUG

For initial injection participants will be given CABENUVA 600-mg/900-mg Kit: (single-dose vial of 600 mg/3 mL (200 mg/mL) cabotegravir , single-dose vial of 900 mg/3 mL (300 mg/mL) rilpivirin).

For subsequent injections participants will be given CABENUVA 400-mg/600-mg Kit: (single-dose vial of 400 mg/2 mL (200 mg/mL) cabotegravir, single-dose vial of 600 mg/2 mL (300 mg/mL) rilpivirine)

CABENUVA® is owned by or licensed to the ViiV Healthcare group of companies, GlaxoSmithKline Research Triangle Park, NC 27709

Etonogestrel (ETG) implant

Intervention Type: DRUG

Contraceptive progestin implants are thin rods inserted under the skin of a woman's arm

Aim 1a (PK study group 3)

Initiating injectable cabotegravir/rilpivirine (LA ART) and levonorgestrel implant.

Group Type: EXPERIMENTAL

Cabotegravir/ Rilpivirine

Intervention Type: DRUG

For initial injection participants will be given CABENUVA 600-mg/900-mg Kit: (single-dose vial of 600 mg/3 mL (200 mg/mL) cabotegravir , single-dose vial of 900 mg/3 mL (300 mg/mL) rilpivirin).

For subsequent injections participants will be given CABENUVA 400-mg/600-mg Kit: (single-dose vial of 400 mg/2 mL (200 mg/mL) cabotegravir, single-dose vial of 600 mg/2 mL (300 mg/mL) rilpivirine)

CABENUVA® is owned by or licensed to the ViiV Healthcare group of companies, GlaxoSmithKline Research Triangle Park, NC 27709

Levonorgestrel

Intervention Type: DRUG

Contraceptive estrogen implants are thin rods inserted under the skin of a woman's arm

Aim 1a (PK study group 4)

Receiving injectable cabotegravir/ rilpivirine (LA ART) and not using any hormonal contraceptive method (e.g. copper IUD)

Group Type: ACTIVE_COMPARATOR

Cabotegravir/ Rilpivirine

Intervention Type: DRUG

For initial injection participants will be given CABENUVA 600-mg/900-mg Kit: (single-dose vial of 600 mg/3 mL (200 mg/mL) cabotegravir , single-dose vial of 900 mg/3 mL (300 mg/mL) rilpivirin).

For subsequent injections participants will be given CABENUVA 400-mg/600-mg Kit: (single-dose vial of 400 mg/2 mL (200 mg/mL) cabotegravir, single-dose vial of 600 mg/2 mL (300 mg/mL) rilpivirine)

CABENUVA® is owned by or licensed to the ViiV Healthcare group of companies, GlaxoSmithKline Research Triangle Park, NC 27709

Aim 1a (PK study group 5)

AGYW without HIV and not exposed to antiretrovirals (e.g., for PrEP) initiating DMPA

Group Type: ACTIVE_COMPARATOR

Intramuscular depo-medroxyprogesterone acetate (IM DMPA)

Intervention Type: DRUG

DMPA (150 mg of depo-medroxyprogesterone acetate (MPA)/ml IMI) is the most commonly used injectable contraceptive worldwide

Aim 2a (Hybrid trial intervention group)

AGYW with viral suppression on their current ART regimen to switch to cabotegravir/ rilpivirine.

Group Type: EXPERIMENTAL

Cabotegravir/ Rilpivirine

Intervention Type: DRUG

For initial injection participants will be given CABENUVA 600-mg/900-mg Kit: (single-dose vial of 600 mg/3 mL (200 mg/mL) cabotegravir , single-dose vial of 900 mg/3 mL (300 mg/mL) rilpivirin).

For subsequent injections participants will be given CABENUVA 400-mg/600-mg Kit: (single-dose vial of 400 mg/2 mL (200 mg/mL) cabotegravir, single-dose vial of 600 mg/2 mL (300 mg/mL) rilpivirine)

CABENUVA® is owned by or licensed to the ViiV Healthcare group of companies, GlaxoSmithKline Research Triangle Park, NC 27709

Aim 2a (Hybrid trial comparator group)

AGYW with viral suppression to continue their oral ART regimen.

Group Type: ACTIVE_COMPARATOR

NNRTI, PI, or INSTI-containing 1st or 2nd line ART regimens

Intervention Type: DRUG

ART that concurrently contains combinations of non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as efavirenz, and protease-inhibitors (PIs), such as atazanavir/ritonavir or lopinavir/ritonavir, or integrase inhibitors (INSTIs), such as raltegravir or dolutegravir

Interventions

Cabotegravir/ Rilpivirine

For initial injection participants will be given CABENUVA 600-mg/900-mg Kit: (single-dose vial of 600 mg/3 mL (200 mg/mL) cabotegravir , single-dose vial of 900 mg/3 mL (300 mg/mL) rilpivirin).

For subsequent injections participants will be given CABENUVA 400-mg/600-mg Kit: (single-dose vial of 400 mg/2 mL (200 mg/mL) cabotegravir, single-dose vial of 600 mg/2 mL (300 mg/mL) rilpivirine)

CABENUVA® is owned by or licensed to the ViiV Healthcare group of companies, GlaxoSmithKline Research Triangle Park, NC 27709

Intervention Type: DRUG

Etonogestrel (ETG) implant

Contraceptive progestin implants are thin rods inserted under the skin of a woman's arm

Intervention Type: DRUG

Intramuscular depo-medroxyprogesterone acetate (IM DMPA)

DMPA (150 mg of depo-medroxyprogesterone acetate (MPA)/ml IMI) is the most commonly used injectable contraceptive worldwide

Intervention Type: DRUG

Levonorgestrel

Contraceptive estrogen implants are thin rods inserted under the skin of a woman's arm

Intervention Type: DRUG

NNRTI, PI, or INSTI-containing 1st or 2nd line ART regimens

ART that concurrently contains combinations of non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as efavirenz, and protease-inhibitors (PIs), such as atazanavir/ritonavir or lopinavir/ritonavir, or integrase inhibitors (INSTIs), such as raltegravir or dolutegravir

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Female sex,
• HIV-positive (for PK groups #1-4) or HIV-uninfected (for PK group #5 only),
• Age 15-24 years at the time of enrollment,
• Documented or confirmed viral suppression for HIV (defined as <40 copies/mL) within 6 months prior to study enrollment,
• Have been on the study oral drug for at least 4 weeks for the PK groups #1-4,
• Have initiated and intends to use DMPA or implant for at least another three or 6 months, respectively,
• Willing to undergo phlebotomy every 4-12 weeks for the duration of the study period
• Able to consent or assent (with parental consent) for study participation in English or Kiswahili

• Participating in PK study for study participants,
• Self-identifying as provider, program person, policy-maker, or stakeholder relevant to the study topics, and age 18 years of age or older,
• Able to consent for study participation in English or Kiswahili

• Female sex,
• HIV-positive,
• Age 15-24 years at the time of enrollment,
• Documented or confirmed viral suppression for HIV (defined as <40 copies/mL) within 6 months prior to study enrollment,
• Willing to undergo phlebotomy every 4-12 weeks for the duration of the study period,
• Able to consent or assent (with parental consent) for study participation in English or Kiswahili

• Participating in hybrid trial study for study participants,
• Self-identifying as provider, program person, policy-maker, or stakeholder relevant to the study topics, and age 18 years of age or older,
• Able to consent for study participation in English or Kiswahili

Exclusion Criteria

• Already be on ART that concurrently contains combinations of non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as efavirenz, and protease-inhibitors (PIs), such as atazanavir/ritonavir or lopinavir/ritonavir, or integrase inhibitors (INSTIs), such as raltegravir or dolutegravir
• Currently pregnant or intends to become pregnant or breastfeeding within the next 12 or 24 weeks for DMPA or implant groups, respectively,
• Have had unprotected sex in the last two weeks or be currently pregnant via urine pregnancy testing,
• Use or anticipated use of drugs for the duration of the study period known to interact with hormonal implants or the study ART regimen,
• Current or planned concomitant use of other hormonal contraceptives,
• Be obese (BMI≥30),
• Evidence of Hepatitis B virus (HBV) infection based on the results of testing for Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (anti-HBc), Hepatitis B surface antibody (anti-HBs) and HBV Deoxyribonucleic acid (DNA) as follows: positive for HBsAg being excluded or negative for anti-HBs but positive for anti-HBc (negative HBsAg status) and positive for HBV DNA are excluded (of note, participants positive for anti-HBc (negative HBsAg status) and positive for anti-HBs (past and/or current evidence) are immune to HBV and are not excluded).
• Serum ALT>5x ULN at the time of screening,
• Serum creatinine >2.5x ULN at the time of screening.

• Already be on ART that concurrently contains combinations of non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as efavirenz, and protease-inhibitors (PIs), such as atazanavir/ritonavir or lopinavir/ritonavir, or integrase inhibitors (INSTIs), such as raltegravir or dolutegravir
• Currently pregnant or intends to become pregnant or breastfeeding within the next one year,
• Have had unprotected sex in the last two weeks or be currently pregnant via urine pregnancy testing,
• Use or anticipated use of drugs for the duration of the study period known to interact with the study ART regimen,
• Evidence of Hepatitis B virus (HBV) infection based on the results of testing for Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (anti-HBc), Hepatitis B surface antibody (anti-HBs) and HBV Deoxyribonucleic acid (DNA) as follows: positive for HBsAg being excluded or negative for anti-HBs but positive for anti-HBc (negative HBsAg status) and positive for HBV DNA are excluded (of note, participants positive for anti-HBc (negative HBsAg status) and positive for anti-HBs (past and/or current evidence) are immune to HBV and are not excluded).
• Serum ALT>5x ULN at the time of screening,
• Serum creatinine >2.5x ULN at the time of screening.

• Minimum Eligible Age: 15 Years
• Maximum Eligible Age: 24 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Moi Teaching and Referral Hospital

OTHER

Sponsor Role: collaborator

Indiana University

OTHER

Sponsor Role: collaborator

University of Nebraska

OTHER

Sponsor Role: collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

Sponsor Role: collaborator

University of Alabama at Birmingham

OTHER

Sponsor Role: lead

Responsible Party

Rena Patel

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Rena Patel, MD, MPH, MPhil

Role: PRINCIPAL_INVESTIGATOR

University of Alabama at Birmingham

Edwin Were

Role: PRINCIPAL_INVESTIGATOR

Moi Teaching and Referral Hospital

Edith Apondi

Role: PRINCIPAL_INVESTIGATOR

MTRH Adolescent Rafiki Clinic and Pediatric Program at AMPATH

Locations

Academic Model Providing Access to Healthcare (AMPATH) Moi Teaching And Referral Hospital (MTRH)

Eldoret, Kenya, Kenya

Site Status: RECRUITING

Countries

Kenya

Central Contacts

Rena Patel, MD, MPH

Role: CONTACT

renapatel@uabmc.edu

205.934.8145

Facility Contacts

Eunice Kaguiri

Role: primary

pipscoordinatoreldoret@gmail.com

Other Identifiers

R01AI155052

Identifier Type: NIH

Identifier Source: secondary_id

View Link

STUDY00012640

Identifier Type: -

Identifier Source: org_study_id